CD4 and pneumocystosis: Second, this work was a retrospective study and we had no access to patient clinical data (antiretroviral treatment regimen, duration, adherence, interruptions of cART, CD4+ count, HIV viral load, CDC stage, anti-tuberculosis treatment, etc.), which would be necessary to fully interpret the impact on PCP.